FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:139-140 January 14, 1993 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Many readers may have missed one of the most interesting items in the September 3 issue of the Journal: the fine print on the back of an advertisement for the Lopid brand of gemfibrozil. Gemfibrozil reduced the incidence of coronary events in the landmark Helsinki Heart Study, reported in the Journal in 1987¹. However, additional information about gemfibrozil that has since become available has received much less attention.

The Warnings section of the prescribing information begins with a reminder that gemfibrozil is chemically, pharmacologically, and clinically similar to clofibrate, which was found in a World Health . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bonneux, L, Barendregt, J J, Ravnskov, U, Ramsay, L E, Yeo, W W, Jackson, P R, Sheldon, T A, Song, F, Millo, J, Sudlow, C L M, Macleod, M R, Heady, J A, Morris, J N, Oliver, M F, Vine, D L, Hastings, G E, Durrington, P N, Dugdale, A, Law, M R, Wu, T, Wald, N J, Hackshaw, A, Bailey, A S G T. (1994). Ischaemic heart disease and cholesterol There's more to heart disease than cholesterol. BMJ 308: 1038-1041 [Full Text]  
• Hulley, S. B., Newman, T. B., Grady, D., Garber, A. M., Baron, R. B., Browner, W. S. (1993). Should We Be Measuring Blood Cholesterol Levels in Young Adults?. JAMA 269: 1416-1419 [Abstract]